Prevalentie en karakteristieken
|
|
- Daisy Evans
- 5 years ago
- Views:
Transcription
1 ESBLAT Symposium 2018 Prevalentie en karakteristieken Veilig voedsel produceren ESBLs humaan Marc Bonten
2 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.
3 Prevalence of ESBL carriage in healthcare settings % among 337 inhabitants from 8 Long-Term Care Facilities (LTCF) 4.2% E. coli, 5,2% K. pneumoniae (all in 1 LTCF) Courtesy Linda Verhoef, RIVM, SNIV study % among 643 inhabitants of 9 LTCF Willemsen et al. Antimicrob Resist Infect Control. 2014;3: % among 1,351 patients at hospital admission 8.6% when admitted from LTCF 7.9% when admitted from home Platteel et al. Clin Microbiol Infect. 2015; 21: % among 1,871 ICU patients receiving SOD 4.4% among 1,928 ICU patients receiving SDD Oostdijk et al. JAMA, Oct 2014
4 Prevalence of ESBL carriage in Dutch population % (95%CI %) daycare children and parents (van der Bunt et al, J Antimicrob Chemother. 2016;10:XXX) % (95% CI ) ESBL/AmpC prevalence among children attending daycare centers; (Koningstein M, et al. J Pediatric Infect Dis Soc. 2015;4(4):e93 9) % (95% CI ) ESBL/AmpC prevalence among adults in living in livestockdense area; (Wielders C., et al. Clin Microbiol Infect. 2017;23:120e1 8) % (95% CI ) overall ESBL/AmpC prevalence in a general population (high and low broiler density area); (Huijbers PMC, et al. Clin Microbiol Infect. 2013;19(6):E256 9) % (95% CI ) ESBL carriage elderly at hospital admission (Platteel TN, et al. Clin Microbiol Infect. 2015;21: ) % (95% CI ) ESBL carriage before travelling (Paltansing S, et al. Emerg Infect Dis. 2013) % (95% CI ) ESBL carriage among citizens of Amsterdam (Reuland EA, et al. J Antimicrob Chemother. 2016;10:1-7) % (95% CI ) patients visiting GP with gastrointestinal complaints (Reuland EA, et al. Clin Microbiol Infect. 2013;19(6):542 9)
5 Prevalence of ESBL carriage in Dutch population % (95%CI %) daycare children and parents (van der Bunt et al, J Antimicrob Chemother. 2016;10:XXX) % (95% CI ) ESBL/AmpC prevalence among children attending daycare centers; (Koningstein M, et al. J Pediatric Infect Dis Soc. 2015;4(4):e93 9) % (95% CI ) ESBL/AmpC prevalence among adults in living in livestockdense area; (Wielders C., et al. Clin Microbiol Infect. 2017;23:120e1 8) % (95% CI ) overall ESBL/AmpC prevalence in a general population (high and low broiler density area); (Huijbers PMC, et al. Clin Microbiol Infect. 2013;19(6):E256 9) % (95% CI ) ESBL carriage elderly at hospital admission (Platteel TN, et al. Clin Microbiol Infect. 2015;21: ) % (95% CI ) ESBL carriage before travelling (Paltansing S, et al. Emerg Infect Dis. 2013) % (95% CI ) ESBL carriage among citizens of Amsterdam (Reuland EA, et al. J Antimicrob Chemother. 2016;10:1-7) % (95% CI ) patients visiting GP with gastrointestinal complaints (Reuland EA, et al. Clin Microbiol Infect. 2013;19(6):542 9)
6 ESBLAT Study design ESBLs in humans (Monthly repeated crosssectional) Prevalence and genotypes in the Dutch human population Risk factors for ESBL carriage in humans ESBLs in pets (Monthly repeated crosssectional) Pets Prevalence and genotypes of ESBLs in Dutch dogs and cats Risk factors for ESBL carriage in dogs and cats Persistence of ESBLs in humans and pets (follow-up after 1 and 6 months after first sample) UMCU/RIVM UU Faculty of Veterinary Medicine
7 ESBLAT Study design: inclusion Dutch general population Humans Invited: n= Participation y/n? Y N Willing to participate in Human Faecal sampling? Faecal sample Y N Questionnaire & faecal sample N= (8,7%) Only questionnaire N= (9,6%) No information N=39.169
8 Representativeness of ESBLAT study population Source: CBS 2017 Netherlands 2015 N=16,900,726 ESBLAT N=4,177 Difference <20 years 22.7% 14.5% -8,2% 20 to 39 years 24.5% 12.5% -12,0% 40 to 64 years 35.1% 45.0% +10,1% 65 to 79 years 13.4% 24.7% +11,3% >80 years 4.3% 3.2% -1,1% Average age population ,5yr Parents both born in the Netherlands 78.3% 97.5% +19,2% Gender (Male) 49.5% 45.5% +4% Degree of urbanization (adresses per km2) >= % 5.4% -17,3% % 15.0% -9,8% % 19.5% +2,2% % 27.9% +10,3% < % 32.2% +14,6% County Groningen / Friesland / Drenthe 10,2% 12,4% +2,2% Overijssel / Flevoland / Gelderland 21,1% 24,3% +3,3% Utrecht / N-Holland / Z-Holland 45,1% 37,5% -7,6% Zeeland / N-Brabant / Limburg 23,6% 25.,6% -2%
9 Participants aggregated per municipality
10 ESBLAT Results Prevalence of ESBL carriage: 186/ % (95%CI: %) E. coli: 178 (93.7%) K. pneumonia: 10 (5.2%) E. cloacae complex: 2 (1.1%) Adjusted for: Prevalence (%) 95% CI Gender Age County Degree of urbanisation Nationality E. coli genotypes: blactx-m15: 85 (44.5%) blactx-m1: 30 (15.7%) blactx-m14: 31 (16.2%) blactx-m27: 27 (14.1%) E. coli sequence types: ST131: 42 (23.6%) ST38: 22 (12.4%) ST10: 14 (7.9%)
11 ESBL positieve participants
12 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.
13 Univariately tested variables (of 86 variables) General characteristics: - Gender - Country of birth is other than the Netherlands - Age - Social Economic Status (SES) - Degree of urbanization - Season of sampling - Year of sampling - Level of education Health care related: - Admission to hospital in 4 weeks prior to sample collection - Hospitalization in the past 12 months - Used antibiotics in 8 weeks prior to sample collection - Used antibiotics in the past (never, <6 months, 6-12 months, >12 months) - Used of proton pump inhibitors in the past 6 months Exposure related: - Attending day care of at least 1 child in household - Ate raw or undercoocked meat 1 week in the past week - Eat no meat - Eat pork - Eat in a restaurant more often than 20 times a year - Being abroad: - in the 4 weeks prior to sample collection - in the past 12 months - Animals in or around the household - Not changing the kitchen towel on a daily basis - Swam: - in sea or ocean ('salt' water) in the past 4 weeks - in sea or ocean ('salt' water) in the past 12 months - in open fresh water (lakes, river, etc.) in the past 4 weeks - in open fresh water (lakes, river, etc.) in the past 12 months
14 ESBLAT: Risk factors identified univariate multivariate* Variable OR 95% CI OR 95% CI Gender (Male) 1,25 0,93 1,68 1,44 1,01 2,05 Country of birth is other than the Netherlands 2,32 1,28 4,19 2,34 1,18 4,61 Eat in a restaurant more often than 20 times a year 1,96 1,33 2,90 1,74 1,09 2,78 used antibiotics in the past never <6 months 2,43 1,28 4,60 2,06 1,02 4, months 1,66 0,96 2,87 1,64 0,73 3,68 >12 months 1,64 0,77 3,48 1,43 0,79 2,59 Ate pork 0,61 0,37 1,02 Swam in sea or ocean ('salt' water) in the past 12 months 1,56 1,14 2,13 1,46 1,0 2,14 Not changing the kitchen towel on a daily basis 2,20 1,41 3,43 2,15 1,27 3,62 Travelled (in the past 12 months): Not travelled to Europe 1,19 0,83 1,69 0,83 0,54 1,29 to Africa 3,85 1,73 8,5 3,03 1,23 7,46 to Asia 3,73 2,18 6,35 2,00 1,02 3,90 to North-America 1,34 0,52 3,46 0,17 0,02 3,62 *controlled for the following variables: age (0-4, 5-12, 12-19, 20-39, 40-64, 95-79, >80) and season (autumn(september November), winter (December February), spring (March May), summer (June August)).
15 633 (34 3%) of 1847 travellers had acquired ESBL-E during international travel, especially in southern Asia (75 1%). Median duration of colonisation after travel was 30 days. 65 (11 3%) of 577 remained colonised at 12 months.
16
17 Prevalence ESBLAT: Traveling to Africa and Asia in the past 12 months 35,00 30,00 25,00 20,00 15,00 10,00 5,00 0,00 ESBL prevalence in participants travelled in the past year % ESBL Continent ESBL N % ESBL Africa ,31 Asia ,00 Europe ,15 North- America ,67 Oceania South- America ,55 Continent
18 ESBLAT: other risk factors Eat more than 20 times a year in a restaurant Associated with travel, higher SES Swam in sea or ocean ('salt' water) in the past 12 months Associated with travelling Not changing the kitchen towel on a daily basis Associated with Not changing the dish towel on a daily basis, Not always cleaning hands before preparing food, Not always cleaning hands after toilet visit
19 Percentage ESBLAT: PPI not a risk factor Reuland EA, et al. J Antimicrob Chemother. 2016;10: ESBLAT: Proton Pump Inhibitor Use per age category >80 Age category and 5,3% in PPI (32/599) % PPI use Subgroup analysis in 40+ group: ESBL + 4,4% (105/2395) in non-ppi
20 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.
21 R 0 R 0 is the average number of new cases of an infection caused by one infected individual in a population of susceptibles R 0 > 1 : each infected spreads the infection to more than one other person/animal: chain reaction = epidemic R 0 < 1 : on average an infected does not replace itself in the infected population: infection cannot grow
22 633 (34 3%) of 1847 travellers had acquired ESBL-E during international travel, especially in southern Asia (75 1%). Median duration of colonisation after travel was 30 days. 65 (11 3%) of 577 remained colonised at 12 months. Onward transmission was found in 13 (7 7%) of 168 household members. The probability of transmitting ESBL-E to another household member was 12%. Calculated effective R0 was around 0.2 (Martin Bootsma personal communication), which might include some overestimation due to false-positive transmission events (no molecular typing).
23 Acquisition of ESBL carriage in Dutch hospitals Rectal carriage of ESBL-E Prevalence at admission % [95% CI/CrI] Prevalence at discharge % [95% CI /CrI] Hospital-acquired prevalence at discharge % [95%CI/Crl] Acquisition rate n/1000 patientdays at risk [95% CI/CrI) SoM study 14 hospitals 8,400 admissions 7.4% [6.2%-8.7%] 9.9% [8.2%-11.8%] 2.5% [1.7%-3.6%] 3.2 [ ] R-GNOSIS study Single hospital 5,450 admissions 6.4% [5.2%-7.8%] 8.7% [6.8%-11.0%] 2.3% [1.3%-3.6%] Results: MCMC model 28.5% cross-transmission 71.5% endogenous selection R= [ ] Mathematical model (data R- GNOSIS study) 7.0% [6.2%-7.8%] 9.3% [8.6%-10.0%] 2.3% [1.7%-2.9%] 3.8 [ ] Kluytmans-van de Bergh, Mens, et al. ICHE 2017
24 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.
25 % Resistamt to 3rd gen cephalosporins Trends in prevalence of ESBL-producing bacteria as a cause of bloodstream infections in ISIS-AR Data from 21 labs E. coli: 3,257-4,035/yr K. pneumoniae: /yr E. coli K. pneumoniae
26 Effect of national policy implemented in 2010 Sales data of antimicrobials for use in animals in the Netherlands DDD/AY for different sectors DD/DJ en DDDAnat % reduction ( ) 64.4% reduction in 2016 to reference year 2009 Fluoroquinolones and 3 rd /4 th -gen cefalosporines usage reduced to a minimum 68% reduction in use of colistin ( ) Purple: turkeys Blue: veal Orange: broilers Light green: pigs Dark green: dairy Jaar 26
27 Clinical suspicion of GNB infection (BC + start Abs) N=9,422 GNB bacteremia N=773 (8,2%) GNB: 3GCeph-S N=709 (7,2%) GNB: 3GCeph-R N=64 (0,7%) 3GCeph-R/all GNB N=64/773 (9%) Rottier et al. CID, 2015
28 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.
29 Courtesy: W. Rottier The association between antibiotic resistance and outcome M 2 : mortality M 2 G 1 : appropriateness of empiric therapy G 1 R 0 : resistance of bacterial strain R 0
30 U -1 X* -1 M 2 : mortality M 2 E -1 T 1 X* -1 : underlying disease U -1 : measurable X* -1 E -1 : exposure to healthcare A -1 : exposure to antibiotics C* -1 : colonizing bacterial strain K -1 : known colonization with bacterial strains A -1 C* -1 K -1 C* 0 F 0 P 0 V* 0 R 0 D 1 G 1 C* 0 : bacterial strain causing infection K 0 : known properties of C* 0 F 0 : infection source P 0 : sepsis severity V* 0 : virulence of bacterial strain R 0 : resistance of bacterial strain K 0 D 1 : source control T 1 : empiric antibiotic therapy G 1 : appropriateness of empiric therapy
31 To retrospectively - determine associations between appropriateness of initial antibiotic treatment and other factors associated with day 30 mortality in patients with ESBL bacteremia in 8 Dutch hospitals. 232 consecutive patients (bacteremia due to E. coli, K. pneumoniae and Enterobacter spp) between 2008 and 2010.
32 Variable Variables associated with day-30 mortality Unadjusted OR in univariate analysis Adjusted OR in multivariable analysis Appropriate therapy No (vs Yes) 1.12 ( ) 1.53 ( ) Charlson index >3 (vs <3) 2.16 ( ) 2.80 ( ) Patient age >75 yr (vs <75) 2.35 ( ) 3.81 ( ) Hospital ward at bacteremia onset ICU (vs other) 3.99 ( ) 2.88 ( ) Bacteremia source Non-UTI (vs UTI) 4.31 ( ) 4.79 ( ) Severe sepsis Yes (vs No) 7.24 ( ) 5.24 ( )
33 GRAND-ABC: Burden of Infections Caused by Antibiotic Resistant Gram-Negative Bacteria in the Netherlands Courtesy: Wouter Rottier
34 Conclusions (1) 1. Prevalence of human carriage with ESBL-producing bacteria. 4,5% in open population 8% in LTCF 8% in hospital 4% in ICU 2. Risk factors for carriage in open population. Travelling (esp Asia and Africa) Salt water exposure (linked to travelling) Restaurant exposure (linked to travelling) Antibiotic use Non-hygienic kitchen behavior
35 Conclusions (2) 3. Transmission of ESBL-producing bacteria. Within household: R 0,2 Within hospital: R 0,06 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5% among invasive E. coli infections 8% among invasive K. pneumoniae infections 0.7% when starting empiric antibiotic therapy for sepsis Prevalence stable during last 7 years 5. Consequences of infections with ESBL-producing bacteria. Transmission of ESBL-producing bacteria. No evidence of increased mortality or increased healthcare burden
36 Acknowledgements Department of Medical Microbiology, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands Gerrita van der Bunt A.C. Fluit L. Hidalgo J. Scharringa J. Vlooswijk L.J.L. Muller G.M.A. Riemens-Zetten Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands: W. Van Pelt L. Mughini-Gras A. Mulder Central Veterinary Institute (CVI) of Wageningen University, Lelystad, the Netherlands D.J. Mevius Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands J. Hordijk M.P. Spaninks A.J. Timmerman J.A. Wagenaar Workgroup ESBL Attribution (ESBLAT): Utrecht University-Institute for Risk Assessment Sciences Utrecht University Department of Infectious Diseases & Immunology University Medical Centre Utrecht National Institute for Public Health and the Environment GD-Animal Health VION-FOOD Group van Drie Group
37 Hypothesis: Infections caused by antibiotic resistant bacteria increase the risk of recurrent infetion. Aim: To quantify the association between antibiotic resistance and the occurrence of recurrent bacteremia. Data source: All blood cultire isolates of Enterobacteriaceae in ISIS- AR, covering 60% of all microbiological culture results since 2010 (analysis till Sept 2016).
38 ESBL ESBL+CRE ESBL ESBL+CRE The absolute risk of a recurrent infection caused by ESBL or ESBL/CRE after a first episode caused by a susceptible isolate was 0.1% (74/ episodes). The estimated number of recurrent bacteremia episodes with ESBL or ESBL/CRE in the Netherlands is 19/year.
39 we used genomics to analyze a systematic 11-yr hospitalbased survey of E. coli associated with bacteremia using isolates collected from across England by the British Society for Antimicrobial Chemotherapy and from the Cambridge University Hospitals NHS Foundation Trust.
40 Proportions of STs during the 11-yr sampling framework. Teemu Kallonen et al. Genome Res. 2017;27: Kallonen et al.; Published by Cold Spring Harbor Laboratory Press
41
42 % Resistamt to 3rd gen cephalosporins E. coli K. pneumoniae
43 Prevalence and relative contributions of hospital acquisition, travel acquisition, within-household transmission, and between-household transmission to the prevalence of ESBL. B/W, between-household transmission rate defined as a fraction of the within-household transmission rate.
44
45
LA-MRSA in the Netherlands: the past, presence and future.
LA-MRSA in the Netherlands: the past, presence and future. Prof. Jaap Wagenaar DVM, PhD With input from Prof. Jan Kluytmans MD, PhD Department of Infectious Diseases and Immunology, Faculty of Veterinary
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationLindsay E. Nicolle University of Manitoba Winnipeg, CANADA
Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA Long Term Care Facilities: Spectrum low acuity assisted living mobile independent Not LTAC high acuity complete functional disability dialysis
More informationBacterial infections complicating cirrhosis
PHC www.aphc.info Bacterial infections complicating cirrhosis P. Angeli, Dept. of Medicine, Unit of Internal Medicine and Hepatology (), University of Padova (Italy) pangeli@unipd.it Agenda Epidemiology
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationMDRO in LTCF: Forming Networks to Control the Problem
MDRO in LTCF: Forming Networks to Control the Problem Suzanne F. Bradley, M.D. Professor of Internal Medicine Division of Infectious Disease University of Michigan Medical School VA Ann Arbor Healthcare
More informationHosted by Dr. Jon Otter, Guys & St. Thomas Hospital, King s College, London A Webber Training Teleclass 1
Andreas Voss, MD, PhD Professor of Infection Control Radboud University Nijmegen Medical Centre & Canisius-Wilhelmina Hospital Nijmegen, Netherlands Hosted by Dr. Jon O0er Guys & St. Thomas NHS Founda
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationMRSA found in British pig meat
MRSA found in British pig meat The first evidence that British-produced supermarket pig meat is contaminated by MRSA has been found in new research commissioned by The Alliance to Save Our Antibiotics
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More information120 mln. 17 mln. The Netherlands. 12 million swine. 100 million poultry. 1,5 million dairy cows. 1 million veal calves. 1,5 million sheep and goats
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationInfection control: Need for robust guidelines
Infection control: Need for robust guidelines Hans Jørn Kolmos MD DMSc Professor, consultant Department of Clinical Microbiology Odense University Hospital hans.joern.kolmos@ouh.regionsyddanmark.dk Combating
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationPresenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationSurveillance of AMR in PHE: a multidisciplinary,
Surveillance of AMR in PHE: a multidisciplinary, integrated approach Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright International
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationTable 2.01 Overview of Surveillance programs in the Netherlands. available since. GP, laboratories Decentral Hospital,
2 Extensive summary In the Netherlands, several surveillance programs have been developed to monitor antimicrobial resistance in important pathogens in different settings (SERIN, SIRIN, ISIS- AR). In addition,
More information(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE
(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement
More informationStudy Protocol. The effects of SDD and SOD on antibiotic resistance in the ICU: A multi-center comparison.
Study Protocol The effects of SDD and SOD on antibiotic resistance in the ICU: A multi-center comparison. November 2009 Version 10 Working title: SDD and SOD and antibiotic resistance in the ICU Local
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationBurden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital
Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationCarbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S
Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***
More informationGram negative bacteraemia
Gram negative bacteraemia David Enoch Consultant Medical Microbiologist PHE Cambridge Cambridge University Hospitals NHS FT Overview Gram negative bacteraemia Changing epidemiology in England Epidemiology
More informationWill 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Thanks for material provided by Marlieke de Kraker & Andrew
More information10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017
10 Golden rules of Antibiotic Stewardship in ICU Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 golden rules of Antibiotic Stewardship in the ICU ID, Pharma & Micro advice
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationSupplementary Online Content
Supplementary Online Content Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial.
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntimicrobial resistance I: Situation and strategies in Europe
Antimicrobial resistance I: Situation and strategies in Europe Global Past, Present and Future Challenges in Risk Assessment Strengthening Consumer Health Protection Berlin, November 30th December 1st,
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationReduction of Antibiotics in poultry meat production. Dutch action plan. Ben Dellaert Director Avined Buenos Aires, 27th October 2016
Reduction of Antibiotics in poultry meat production Dutch action plan Ben Dellaert Director Avined Buenos Aires, 27th October 2016 Content 1. Results 2. Motives 3. Policy and collaboration 4. Action plan
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationSurveillance of Multi-Drug Resistant Organisms
Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationA summary index for antimicrobial resistance in food animals in the Netherlands
Havelaar et al. BMC Veterinary Research (2017) 13:305 DOI 10.1186/s12917-017-1216-z RESEARCH ARTICLE A summary index for antimicrobial resistance in food animals in the Netherlands Arie H. Havelaar 1,2,3*,
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationTraveling (resistant) bacteria
Traveling resistant bacteria Erika Vlieghe Institute of Tropical Medicine, Antwerp University Hospital Antwerp Traveling (resistant) bacteria Colonisation - carriership rectal flora, skin Infection: mild-moderate
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationCDI Management in Post-Acute Care: Part 1
CDI Management in Post-Acute Care: Part 1 Robin Jump, MD, PhD VISN10 Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University Robin.Jump@va.gov
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More informationEFSA s activities on Antimicrobial resistance in the food chain. Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA
EFSA s activities on Antimicrobial resistance in the food chain Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA EFSA IS The reference body for risk assessment of food and feed in the European Union. Its
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationEVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY
EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY G E B R A E L S A L I B A, M D, M P H C L I N H D F 2017 U N I V E R S I T É S A I N
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationMRSA control strategies in Europekeeping up with epidemiology?
MRSA 15 years in Belgium MRSA control strategies in Europekeeping up with epidemiology? Marc J. Struelens, MD, PhD Senior Expert, Scientific Advice Unit European Centre for Disease Prevention and Control,
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationAntibiotic resistance in West Africa
Antibiotic resistance in West Africa Prof. Pierre Tattevin Infectious Diseases and ICU, Pontchaillou University Hospital, Rennes, France International Society of Chemotherapy No conflict of Interest International
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationHEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE
Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationAnimal Antibiotic Use and Public Health
A data table from Nov 2017 Animal Antibiotic Use and Public Health The selected studies below were excerpted from Pew s peer-reviewed 2017 article Antimicrobial Drug Use in Food-Producing Animals and Associated
More informationA Point Prevalence Survey of Antibiotic Prescriptions and Infection in Sanandaj Hospitals, Prospects for Antibiotic Stewardship
A Point Prevalence Survey of Antibiotic Prescriptions and Infection in Sanandaj Hospitals, Prospects for Antibiotic Stewardship Jafar Soltani* Ann Versporten**, Behzad Mohsenpour*, Herman Goossen**, Soheila
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationTaking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms
Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National
More informationIntroduction to antimicrobial resistance
Introduction to antimicrobial resistance Philip Howard Consultant Antimicrobial Pharmacist HCAI and AMR Project Lead 4 th March 2015 What is antimicrobial resistance? Antibacterials either kill or stop
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationDr.Asad A. Khan FRCPC Consultant, Division of Infectious Diseases Tawam Hospital Al Ain, UAE
MDR Enterobacteriaceae in community acquired infections Dr.Asad A. Khan FRCPC Consultant, Division of Infectious Diseases Tawam Hospital Al Ain, UAE Introduction Case presentation Epidemiology Objectives
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationQuestions and answers about methicillin-resistant Staphylococcus aureus (MRSA)
Questions and answers about methicillin-resistant Staphylococcus aureus (MRSA) Updated FAQ, 18 November 2014 Methicillin-resistant Staphylococcus aureus (MRSA) are bacteria which are resistant to certain
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationMRSA in the United Kingdom status quo and future developments
MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L
More informationExploring the Role of Antibiotics on VRE Colonization and Infection
Exploring the Role of Antibiotics on VRE Colonization and Infection Dr. James McKinnell, Dr. Loren Miller, Dr. Arnold Bayer K30 Fellow Harbor-UCLA/University of Alabama Background Enterococcus Spp. are
More informationEFSA s activities on Antimicrobial Resistance
EFSA s activities on Antimicrobial Resistance CRL-AR, Copenhagen 23 April 2009 Annual Workshop of CRL - AR 1 Efsa s Role and Activities on AMR Scientific advices Analyses of data on AR submitted by MSs
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES
ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationEFSA s activities on antimicrobial resistance in the food chain: risk assessment, data collection and risk communication.
EFSA s activities on antimicrobial resistance in the food chain: risk assessment, data collection and risk communication. Dr. Ernesto Liebana BIOHAZ Team Leader European Food Safety Authority (EFSA) EFSA
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationInforming Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO
Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO Stephen J. DeVincent, DVM, MA Director, Ecology Program Alliance for the Prudent Use of
More informationOrigins of Resistance and Resistance Transfer: Food-Producing Animals.
Origins of Resistance and Resistance Transfer: Food-Producing Animals. Chris Teale, AHVLA. Origins of Resistance. Mutation Brachyspira hyodysenteriae and macrolide and pleuromutilin resistance. Campylobacter
More information2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea
2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea Submitted by: Asia Pacific Foundation for Infectious Diseases Policy Forum on Strengthening Surveillance and Laboratory Capacity to
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationVaccine Evaluation Center, BC Children s Hospital Research Institute, 950 West 28 th Ave,
Manuscript Click here to view linked References Age-specific trends in antibiotic resistance in Escherichia coli infections in Oxford, United Kingdom 2013-2014 Rebecca C Robey a, Simon B Drysdale b,c,
More informationTHE NETHERLANDS VETERINARY MEDICINES AUTHORITY
THE NETHERLANDS VETERINARY MEDICINES AUTHORITY Workshop Lithuania, Oktober 2016 Reducing usage of antimicrobials in livestock: The Dutch approach Hetty van Beers-Schreurs, DVM, PhD SHORT INTRODUCTION Educated
More informationHuman health impacts of antibiotic use in animal agriculture
Human health impacts of antibiotic use in animal agriculture Beliefs, opinions, and evidence Peter Davies BVSc, PhD College of Veterinary Medicine, University of Minnesota, USA Terminology Antibiotic Compound
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More information